The acquisition is expected to close in the third quarter of 2026.
The UK Government has prioritised life science sector growth, but industry members have called for more funding.
The decision is based on data from the pivotal Phase III EPCORE FL-1 trial.
Roche’s breast cancer agreement with Astex is one of several oncology deals the Swiss pharma giant has inked in recent years.
The transaction will see UniD Manufacturing rebranded as Besins Healthcare PharmTech.
Paris is emerging as a focal point for Europe’s next phase in oncology, as science, capital and industry converge at Campus Grand Parc.
